These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

53 related articles for article (PubMed ID: 10914155)

  • 1. [Use of abciximab (Reopro) in the catheterization laboratory and in unstable coronary syndromes].
    Banai S; Keren A; Daniel N; Benhorin J
    Harefuah; 1999 Jan; 136(1):29-34, 95, 94. PubMed ID: 10914155
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early and late clinical outcome following coronary angioplasty performed with platelet glycoprotein IIb/IIIa receptor inhibition: the EPIC Trial results.
    Popma JJ; Satler LF
    J Invasive Cardiol; 1994; 6 Suppl A():19A-28A; discussion 45A-50A. PubMed ID: 10155090
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The initial experience of the use of ReoPro in high-risk coronary angioplasty in Italy: the Italian Registry on the Conditions for the Use of ReoPro during Angioplasty (R.I.CO.R.D.A.)].
    Simonetti I; Gallopin M; Klugmann S; Gensini GF
    Ital Heart J Suppl; 2000 Jan; 1(1):88-96. PubMed ID: 10832124
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors.
    Adgey AA
    Eur Heart J; 1998 Apr; 19 Suppl D():D10-21. PubMed ID: 9597518
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Frequency and efficacy of glycoprotein IIb/IIIa therapy for treatment of threatened or acute vessel closure in 1332 patients undergoing percutaneous transluminal coronary angioplasty.
    Haase KK; Mahrholdt H; Schröder S; Baumbach A; Oberhoff M; Herdeg C; Karsch KR
    Am Heart J; 1999 Feb; 137(2):234-40. PubMed ID: 9924156
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Platelet aggregatory response to platelet activating factor (PAF), ex vivo, and PAF-acetylhydrolase activity in patients with unstable angina: effect of c7E3 Fab (abciximab) therapy.
    Tselepis AD; Goudevenos JA; Tambaki AP; Michalis L; Stroumbis CS; Tsoukatos DC; Elisaf M; Sideris DA
    Cardiovasc Res; 1999 Jul; 43(1):183-91. PubMed ID: 10536703
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Initial experience with the use of abciximab in the salvage treatment of acute coronary thrombosis in the Hemodynamics Laboratory].
    Rubboli A; Fransson SG; Wiklund G; Sangiorgio P; Bracchetti D; Stenport G
    Cardiologia; 1998 Nov; 43(11):1221-9. PubMed ID: 9922589
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of coronary angiograms prior to and after treatment with abciximab, and the outcome of angioplasty in refractory unstable angina patients. Angiographic results from the CAPTURE trial.
    van den Brand M; Laarman GJ; Steg PG; De Scheerder I; Heyndrickx G; Beatt K; Kootstra J; Simoons ML
    Eur Heart J; 1999 Nov; 20(21):1572-8. PubMed ID: 10529325
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Dissolution of acute stent thrombosis by abciximab bolus].
    Russo G; Nicosia A; Tamburino C; Mammana C; Galassi AR; Monaco A; Grassi R; Calvi V; Giuffrida G
    Cardiologia; 1998 Jun; 43(6):631-4. PubMed ID: 9675963
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiplatelet therapy in therapy-resistant unstable angina. A pilot study with REO PRO (c7E3).
    van den Brand MJ; Simoons ML; de Boer MJ; van Miltenburg A; van der Wieken LR; de Feyter PJ
    Eur Heart J; 1995 Nov; 16 Suppl L():36-42. PubMed ID: 8869017
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduction of recurrent ischemia with abciximab during continuous ECG-ischemia monitoring in patients with unstable angina refractory to standard treatment (CAPTURE).
    Klootwijk P; Meij S; Melkert R; Lenderink T; Simoons ML
    Circulation; 1998 Oct; 98(14):1358-64. PubMed ID: 9760288
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. c7E3 Fab Antiplatelet Therapy in Unstable Refractory Angina (CAPTURE) Study Investigators.
    Hamm CW; Heeschen C; Goldmann B; Vahanian A; Adgey J; Miguel CM; Rutsch W; Berger J; Kootstra J; Simoons ML
    N Engl J Med; 1999 May; 340(21):1623-9. PubMed ID: 10341274
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Usefulness of platelet glycoprotein IIb/IIIa inhibitors in coronary stenting for reconstruction of complex lesions: procedural and 30 day outcome.
    Galassi AR; Russo G; Nicosia A; Tamburino C; Foti R; Rodi G; Calvi V; Gulizia G; Distefano G; Moshiri S; Giuffrida G
    Cardiologia; 1999 Jul; 44(7):639-45. PubMed ID: 10476589
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical safety using the thrombocyte aggregation inhibitor c7E3 in interventional cardiology in 520 patients].
    Machnig T; Zahn R; Rustige J; Gödicke J; Marsalek P; Gulba D
    Z Kardiol; 1997 Dec; 86(12):975-81. PubMed ID: 9499495
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does platelet glycoprotein IIb/IIIa receptor antibody improve in-hospital outcome of coronary stenting in high-risk thrombus containing lesions?
    Piamsomboon C; Wong PM; Mathur A; Singh D; Liu MW; Baxley WA; Iyer SS; Dean LS; Roubin GS
    Catheter Cardiovasc Interv; 1999 Apr; 46(4):415-20. PubMed ID: 10216005
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization.
    EPILOG Investigators
    N Engl J Med; 1997 Jun; 336(24):1689-96. PubMed ID: 9182212
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential inhibition of platelet aggregation induced by adenosine diphosphate or a thrombin receptor-activating peptide in patients treated with bolus chimeric 7E3 Fab: implications for inhibition of the internal pool of GPIIb/IIIa receptors.
    Kleiman NS; Raizner AE; Jordan R; Wang AL; Norton D; Mace KF; Joshi A; Coller BS; Weisman HF
    J Am Coll Cardiol; 1995 Dec; 26(7):1665-71. PubMed ID: 7594101
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial.
    Kastrati A; Mehilli J; Neumann FJ; Dotzer F; ten Berg J; Bollwein H; Graf I; Ibrahim M; Pache J; Seyfarth M; Schühlen H; Dirschinger J; Berger PB; Schömig A;
    JAMA; 2006 Apr; 295(13):1531-8. PubMed ID: 16533938
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of the platelet glycoprotein IIb/IIIa inhibitor abciximab in Chinese patients undergoing high-risk angioplasty.
    Chen YH; Chen JW; Wu TC; Ding PY; Wang SP; Chang MS
    Zhonghua Yi Xue Za Zhi (Taipei); 2000 Jan; 63(1):8-15. PubMed ID: 10645045
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antithrombotic effects of abciximab.
    Hayes R; Chesebro JH; Fuster V; Dangas G; Fallon JT; Sharma SK; Coller BS; Badimon L; Marmur JD; Badimon JJ
    Am J Cardiol; 2000 May; 85(10):1167-72. PubMed ID: 10801995
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.